Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/26773
Başlık: Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: A randomized evaluation of early vs late administration of recombinant human G-CSF
Yazarlar: Topçuoǧlu, Pervin
Beksac, M. S.
Özcan, Muhit
Arat, Mutlu
Bykl, Z.
Bakanay, Şule Mine
İlhan, Osman
Gürman, Günhan
Arslan, Önder
Demirer, Taner
Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Anabilim Dalı.
Özçelik, Tülay
7005424333
Anahtar kelimeler: G-CSF
Mobilization
SCT
Blood stem-cells
Colony-stimulating factor
Multiple-myeloma patients
10 mu-g/kg
Progenitor cells
Delayed addition
Breast-cancer
Cyclophosphamide
Collection
Transplantation
Biophysics
Oncology
Hematology
Immunology
Transplantation
Yayın Tarihi: Ara-2009
Yayıncı: Springernature
Atıf: Özçelik, T. vd. (2009). "Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: A randomized evaluation of early vs late administration of recombinant human G-CSF". Bone Marrow Transplantation, 44(12), 779-783.
Özet: The optimal timing for recombinant human (rh)G-CSF administration after chemotherapy for PBSC mobilization has not yet been determined. In this study, we compared two different time schedules of rhG-CSF; 4th (early) vs 7th day (late), in 48 consecutive patients with multiple myeloma and lymphoma undergoing PBSC mobilization with CE (CY 4 g/m(2) on day 1 and etoposide 200 mg/m(2) on days 1-3). The rhG-CSF dose was 10 mu g/kg/day for all patients. Both groups were comparable in terms of sex, age and number of previously given different chemotherapy regimens. Duration of neutropenia, CD34(+) cell count on the first day of apheresis and numbers of aphereses were not statistically different between the two arms. However, the number of doses of rhG-CSF up to the first cycle of apheresis procedures was significantly lower in the late group than in the early group (P-0.005). The median number of total CD34(+) cells collected was 10.54 x 10(6)/kg (range 0.11-37.27) in the early group and 10.81 x 10(6)/kg (range 0.17-49.83) in the late group of rhG-CSF (P-0.781). We conclude that PBSC mobilization after late use of rhG-CSF is an effective approach and therefore, in routine clinical practice, late rhG-CSF may be used for PBSC collections after chemotherapybased mobilization regimens in this cost-conscious era.
URI: https://doi.org/10.1038/bmt.2009.161
https://www.nature.com/articles/bmt2009161
http://hdl.handle.net/11452/26773
ISSN: 0268-3369
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.